Drugs / Histamine Human Immunoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06250400 | Mar 2024 → Jul 2025 | chronic idiopathic urticaria | Hangzhou Grand Biologic Pharmaceutical, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Histamine Human Immunoglobulin | “Histamine Human Immunoglobulin (ShuYangMinNing)” NCT06250400 ↗ |
| Known as | ShuYangMinNing | “Histamine Human Immunoglobulin (ShuYangMinNing)” NCT06250400 ↗ |
| Route | Subcutaneous | “2 subcutaneous injection once a week” NCT06250400 ↗ |